


Finding the Face in the Crowd

Translational Research in a Global Competitive Scientific Market

TRANSLATE!

May 23–24, 2016
Berlin, Germany
Hotel Mövenpick



www.science-translate.com

Monday, May 23rd (1)

9:00 am REGISTRATION

10:00 am WELCOME

Georg Schütte	State Secretary <i>Federal Ministry of Education and Research</i>
Günther Wess	Vice-President Research Field Health <i>Helmholtz Association</i>
Ernst Rietschel	Former CEO <i>Berlin Institute of Health</i>
Karl Einhäupl	Chairman of the Executive Board <i>Charité – Universitätsmedizin Berlin</i>
Megan Frisk	Associate Editor <i>Science Translational Medicine</i>
Georg Duda	Deputy Director <i>Berlin-Brandenburg Center for Regenerative Therapies</i>

10:30 am SESSION 1: BALANCING RISKS AND BENEFITS IN TRANSLATIONAL RESEARCH

MODERATOR: HANS-DIETER VOLK | *BERLIN-BRANDENBURG CENTER FOR REGENERATIVE THERAPIES*

Translational research is hindered by several common obstacles. In addition to insufficient resources and an increasing regulatory burden, there exists a lack of specific mechanisms for considering both the value of the research as well as the risks involved in order to find a proper risk-benefit balance. The session will focus on de-risking strategies that could be implemented to revive and improve processes for translational medicine and contribute more efficiently to clinical success for novel therapeutics and innovative medical devices.

- Translational research within universities and beyond Hans-Gustaf Ljunggren | *Karolinska Institutet*
- Challenges of moving academic research into the clinic and beyond Jeffrey Bluestone | *UCSF School of Medicine*
- Regulatory aspects in the translation of gene and cell therapies Martina Schuessler-Lenz | *Paul-Ehrlich-Institut*
- Consensus data standards – Unified data for biomarkers with focus on regulatory science Klaus Romero | *Critical Path Institute*

12:30 pm LUNCH BREAK

1:45 pm PANEL 2: FROM REACTIVE TO PROACTIVE TRANSLATIONAL MEDICINE

MODERATOR: GEORG DUDA | *BERLIN-BRANDENBURG CENTER FOR REGENERATIVE THERAPIES*

Translational research has been criticized for having little influence on clinical practice. One approach to achieving more relevance is to conduct research using appropriate methods that balance the interests of scientific researchers, clinicians and policymakers. Convening a group of world-renowned experts with varying viewpoints, this panel will focus on different aspects of translation, such as how to assess a candidate project for funding opportunities, how to bring diverse groups to the translational research process, what measures need to be taken to establish a strong clinical research infrastructure, and what is the role of governments in speeding up the translational research process?

- Accelerating the pace at which lifesaving treatments reach patients Heyo K. Kroemer | *Universitätsmedizin Göttingen*
- Catalyzing Translational Innovation Petra Kaufmann | *NIH National Center for Advancing Translational Sciences (NCATS)*
- Governmental influences on drug development: How to strike a better balance? Günther Wess | *Helmholtz Association*
- How can regulators and scientists improve translation? Barbara Casadei | *University of Oxford*


3:30 pm COFFEE BREAK

Finding the Face in the Crowd

Translational Research in a
Global Competitive Scientific Market

TRANSLATE!

May 23–24, 2016
Berlin, Germany



www.science-translate.com

Monday, May 23rd (2)

4:00 pm

SESSION 3: PARALLEL BREAKOUT SESSIONS

30-35 PARTICIPANTS PER SESSION | 15 MIN INTRODUCTION BY SESSION CHAIR FOLLOWED BY DISCUSSION

In these breakout sessions, participants are broken up into smaller groups for the purpose of discussing specific topics. This session is particularly important in developing, in detail, action items for high-priority areas of translational medicine. The focus lies on synthesizing new ideas and presenting a consensus on Day 2 from the group on how to move forward in various areas.

1. Mentoring the next generation of clinical and translational researchers

Chair: **Marc McKee** | *McGill University*

Co-Chair: **Georg Duda** | *Berlin-Brandenburg Center for Regenerative Therapies*

2. Animal models in biomedical research: Improving utility and translation – cancer research and therapeutics as an example

Chair: **Robert Kerbel** | *University of Toronto*

Co-Chair: **Ulrich Dirnagl** | *Charité Universitätsmedizin - Berlin*

3. Citizen Science - Opportunities and Challenges for Translational Research

Chair: **Ernst Hafen** | *ETH Zürich*

Co-Chair: **Holger Gerhardt** | *Max Delbrück Center for Molecular Medicine*

4. Business and entrepreneurial aspects of translational medicine

Chair: **Glenn Prestwich** | *University of Utah*

Co-Chair: **Paulo Fontoura** | *Roche*

5. Clinical Research Units – Solution for integrating Translational Research into the clinical practice. Industry and clinical perspectives)

Chair: **Ronenn Roubenoff** | *Novartis Institutes for Biomedical Research*

Chair: **Barbara Casadei** | *University of Oxford*

Co-Chair: **Mohamed Abou El-Enein** | *Berlin-Brandenburg Center for Regenerative Therapies*

5:30 pm

BREAK

6:30 pm

DINNER WITH SHORT TALKS

tba

Marc McKee | *McGill University*

Speeding up drug discovery and development: The Human Brain Project approach

Richard Frackowiak | *Université de Lausanne*

8:30 pm


END OF FIRST DAY

Finding the Face in the Crowd

Translational Research in a
Global Competitive Scientific Market

TRANSLATE!

May 23–24, 2016
Berlin, Germany



www.science-translate.com

Tuesday, May 24th (1)

9:30 am

WAKE UP & SUMMARY OF FIRST DAY

DAVID GRAINGER | *UNIVERSITY OF UTAH*

9:45 am

PANEL 4: BEING EFFICIENT IN ADVANCING TRANSLATIONAL RESEARCH

MODERATOR: DAVID GRAINGER | *UNIVERSITY OF UTAH*

Pressing issues in translation are the continuously rising cost of new drugs, especially for serious and life-threatening conditions, and the slow pace of device approval. Drug prices are a result of the complex and lengthy drug development and an approval process that can take a dozen years and billions of dollars. Currently, drug and device development is a rather inefficient and expensive undertaking, which leads to enormous economic burden, lack of innovation and new product introductions. The session will focus on addressing the issue of being efficient in different research fields in order to advance translational research.

- **Accelerating translational research in cancer** Robert C. Bast, Jr. | *MD Anderson Cancer Center*
- **Successful strategies across the early-stage translational research** Paulo Fontoura | *Roche*
- **New approaches to value-driven drug development** Stefanie Dimmeler | *University of Frankfurt*
- **From Systems Biology to Systems Medicine: The art is in the integration** Rudi Balling | *University of Luxembourg*
- **Strengthening external research partnerships, particularly with industry** Abhay Pandit | *National University of Ireland*

11:00 am

COFFEE BREAK

11:30 am

SESSION 5: SUMMARIES OF BREAKOUT SESSIONS

1. Mentoring the next generation of clinical and translational researchers Marc McKee | *McGill University*
2. Animal models in biomedical research: Improving utility and translation – cancer research and therapeutics as an example Robert Kerbel | *University of Toronto*
3. Citizen Science - Opportunities and Challenges for Translational Research Ernst Hafen | *ETH Zürich*
4. Business and entrepreneurial aspects of translational medicine Glenn Prestwich | *University of Utah*
5. Clinical Research Units – Solution for integrating Translational Research into the clinical practice. Industrial and clinical perspectives Ronenn Roubenoff | *Novartis Institutes for Biomedical Research*

1:00 pm

LUNCH BREAK

Finding the Face in the Crowd

Translational Research in a
Global Competitive Scientific Market

TRANSLATE!

May 23–24, 2016
Berlin, Germany



www.science-translate.com

Tuesday, May 24th (2)

2:00 pm **SESSION 6: TRANSLATIONAL MEDICINE SUCCESSES IN GLOBAL HEALTH**

MODERATOR: MEGAN FRISK | *SCIENCE TRANSLATIONAL MEDICINE*

The progress of translational medicine has attracted attention of the scientific community and it has been linked to promising potential for global health gain. However, there are still major obstacles related to patent protection, funding and delivering new treatments faster to patients in need. This session will focus on addressing the issues of how important translational medicine is becoming to medical practice, and how far it still has to go to benefit the global community.

- **The development of next-generation regenerative solutions for global health** Andre Terzic | *Mayo Clinic*
- **Developing critical research and training infrastructure with limited resources** Jackson Orem | *Uganda Cancer Institute*
- **The art of funding biomedical innovation: A global perspective** Edward Holmes | *University of California*

3:15 pm **COFFEE BREAK**

- **Accelerating the translation of global health innovations toward real solutions for the benefit of patients** Steve Kern | *Bill & Melinda Gates Foundation*
- **Evaluating and developing translational products** David Mooney | *Harvard University*
- **Efficient translational strategies: Innovations that connect with the heart** Volkmar Falk | *Deutsches Herzzentrum Berlin (tbc)*

4:30 pm **CLOSING REMARKS**

MEGAN FRISK | *SCIENCE TRANSLATIONAL MEDICINE*

GEORG DUDA | *BERLIN-BRANDENBURG CENTER FOR REGENERATIVE THERAPIES*